Stage4Hope Launches to Transform Advanced-Stage Cancer Care
Stage4Hope Launches to Support Patients with Cancer
Stage4Hope™, a new 501(c)(3) nonprofit founded by stage IV lung cancer patient Stacy L. Carter, launches to accelerate access to expert cancer care, provide emotional and financial support, and advance precision oncology research.
We are pleased to announce the official launch of Stage4HopeTM, a 501(c)(3) public charity! We have a powerful mission: to improve the lives of individuals diagnosed with advanced-stage cancer by accelerating access to world-class cancer care, providing financial and emotional support, and investing in cutting-edge research in precision oncology.
Founded by Stacy L. Carter—a mother, entrepreneur, and non-smoker diagnosed with stage IV lung cancer in 2023—Stage4Hope was born out of her own journey and the urgent need to bring hope, clarity, and purpose to others facing similar diagnoses.
“I started Stage4Hope because I know what it’s like to hear the words ‘stage IV’ and to have my whole world fall apart,” says Stacy. “What carried me forward was finding purpose in the midst of the pain. Now, we’re building a place where patients can access expert care quickly, find emotional healing, and rediscover hope and purpose—even in the middle of the storm.”
Read more by downloading the media release>
Top Questions to Ask After a Lung Cancer Diagnosis
If you or a loved one has been diagnosed with lung cancer, knowing what questions to ask can make a major difference in your treatment journey. Dr. Mark Awad, a leading lung cancer expert at Memorial Sloan Kettering (MSK), emphasizes the importance of understanding your specific type and stage of lung cancer — whether it’s small cell or non-small cell — and making sure all the necessary scans have been done to determine where the cancer is in the body. It’s also vital to ask about comprehensive genomic and biomarker testing, which can uncover genetic mutations and guide your doctors to the most effective, personalized treatment options, including immunotherapy or targeted drugs.
Dr. Awad also stresses the value of being treated by a dedicated lung cancer team with extensive experience, and encourages patients to seek a second opinion to ensure the best care. While starting treatment quickly may feel urgent, gathering complete information first often leads to better long-term outcomes. Many treatment centers, including MSK, offer care options closer to home and provide support services to help manage side effects, improve quality of life, and support emotional and practical needs. Most importantly, communicate openly with your care team about your goals and what’s most meaningful to you — so your treatment can support your whole life, not just your diagnosis. (Source: Memorial Sloan Kettering Cancer Center)
Hope for KRAS-G12D Lung Cancer
KRAS-G12D Lung Cancer Clinical Trial Shows Promising Results
Memorial Sloan Kettering Cancer Center researchers have reported promising results from a first-of-its-kind clinical trial targeting the KRAS-G12D mutation in non-small cell lung cancer (NSCLC). The experimental drug zoldonrasib (RMC-9805) demonstrated significant tumor shrinkage in 61% of participants who had previously not responded to standard treatments. These findings offer hope for patients with this challenging mutation subtype.
- « Previous
- 1
- 2
- 3
- 4
